Defensin HNP-1 human (TFA)

Defensin HNP-1 human TFA is a type of human neutrophil peptide (HNPs) . Defensin HNP-1 human TFA possesses immunomodulatory functions and can delay the apoptosis of neutrophils. Defensin HNP-1 human TFA inhibits DNA/RNA/protein synthesis and interferes with metabolic pathways, thus exhibiting broad antibacterial activity. Defensin HNP-1 human TFA has direct inactivation effects on HIV, HSV-1, HSV-2, CMV, influenza virus, etc. Defensin HNP-1 human TFA has antileishmanial activity. Defensin HNP-1 human TFA is involved in endothelial cell dysfunction during the early development of atherosclerosis[1][2][3].

Product Specifications

UNSPSC

12352209

Target

Apoptosis; Bacterial; CMV; DNA/RNA Synthesis; HIV; HSV; Influenza Virus; Interleukin Related; NOD-like Receptor (NLR) ; Parasite; TNF Receptor

Type

Peptides

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Infection

Assay Protocol

https://www.medchemexpress.com/defensin-hnp-1-human-tfa.html

Purity

99.91

Solubility

H2O : ≥ 50 mg/mL

Smiles

O=C(N[C@H]1CC2=CNC3=CC=CC=C23)[C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CCC(N)=O)NC([C@H](CC4=CC=C(O)C=C4)NC([C@]([H])([C@H](CC)C)NC([C@]5(NC([C@]([H])([C@@H](C)O)NC(CNC([C@H](CC6=CC=C(O)C=C6)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)NC(CNC([C@H](C)NC([C@]([H])([C@H](CC)C)NC([C@@]7(CSSC[C@]([H])(NC([C@H](CC8=CC=CC=C8)NC([C@H](C)NC1=O)=O)=O)C(N[C@H](C(O)=O)CSSC[C@H](NC([C@H](C)N)=O)C(N[C@@H](CC9=CC=C(O)C=C9)C(N[C@]([H])(C(N[C@@H](CCCNC(N)=N)C(N[C@@]([H])([C@H](CC)C)C(N%10[C@]([H])(C(N[C@@H](C)C(N7)=O)=O)CCC%10)=O)=O)=O)CSSC5)=O)=O)=O)[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[H])=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

Molecular Formula

C160H227F15N44O48S6

Molecular Weight

4012.15

References & Citations

[1]Dabirian S, et, al. Human neutrophil peptide-1 (HNP-1) : a new anti-leishmanial drug candidate. PLoS Negl Trop Dis. 2013 Oct 17;7 (10) :e2491.|[2]Higazi M, et, al. Opposing effects of HNP1 (α-defensin-1) on plasma cholesterol and atherogenesis. PLoS One. 2020 Apr 17;15 (4) :e0231582.|[3]Zhang J, et al. HNP-1: From Structure to Application Thanks to Multifaceted Functions. Microorganisms. 2025 Feb 19;13 (2) :458.